Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer

INTRODUCTION: Rapamycin acts synergistically with platinum agents to induce apoptosis and inhibit proliferation in breast cancer cell lines. Combination of everolimus also known as RAD001 (oral mammalian target of rapamycin (mTOR) inhibitor) and carboplatin may have activity in metastatic triple-neg...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Jasmeet Chadha, Novik, Yelena, Stein, Stacey, Volm, Matthew, Meyers, Marlene, Smith, Julia, Omene, Coral, Speyer, James, Schneider, Robert, Jhaveri, Komal, Formenti, Silvia, Kyriakou, Victoria, Joseph, Benson, Goldberg, Judith D, Li, Xiaochun, Adams, Sylvia, Tiersten, Amy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053575/
https://www.ncbi.nlm.nih.gov/pubmed/24684785
http://dx.doi.org/10.1186/bcr3634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053575/
https://www.ncbi.nlm.nih.gov/pubmed/24684785
http://dx.doi.org/10.1186/bcr3634

Ejemplares similares